Clinical trials: Plasma Cell Disorder, open to volunteers
Multiple Myeloma, Smoldering Multiple Myeloma
A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
The purpose of this study is to determine the efficacy of treating patients with intermediate risk smoldering multiple myeloma (SMM) with combinational therapy with dexamethasone and lenalidomide (Rd) and patients with high risk…
- Trial name
- iStopMM (NCT03815279)
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- Iceland
- Volunteers
- 80 people
- Sponsor
- Landspitali University Hospital
Multiple Myeloma or Plasmacytoma
Engineered Dendritic Cell Vaccines for Multiple Myeloma
The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac).
- Trial name
- NCT06435910
- Testing
- DC vaccines
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Lymphoma, Large B-Cell, Diffuse
Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL
A prospective, single center, randomized, clinical controlled study to evaluate the efficacy and prognosis differences between precision treatment based on plasma cfDNA testing results and the current conventional diagnostic and…
- Trial name
- NCT06289959
- Testing
- cfDNA
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Multiple Myeloma, Fall Risk Factors
Fall Risk Assessment and an Exercise Intervention for Prevention of Falls in Multiple Myeloma Patients
Approximately one third of the population over the age of 65 falls at least once a year. The risk of falling is in increased in older patients with tumor diseases.
- Conditions
- Multiple Myeloma, Fall Risk Factors, Strength Training Effects, Balance Training Effects
- Trial name
- Myfall (NCT07044427)
- Testing
- Strength and balance training in combination with a treadmill-based pertubation intervention
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University Hospital Heidelberg
Thrombocytopenia
Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias
The purpose of this study is to study how avatrombopag (the study drug) may prevent certain side effects in adults with lymphoma and myeloma getting cancer treatment (CAR-T cell therapy).
- Trial name
- CAR-T 002 (NCT07895017)
- Testing
- Avatrombopag
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Virginia
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd)…
- Trial name
- Iber-KDd (NCT05896228)
- Testing
- Iberdomide, Carfilzomib, Daratumumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Benjamin T Diamond, MD
Multiple Myeloma, Relapse Multiple Myeloma
Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma
This is an open label, abbreviated (3+3) dose escalation study in subjects with RRMM, followed by an extension phase at the selected safe dose.
- Trial name
- NCT05243212
- Testing
- CAR-BCMA
- Where
- Israel
- Volunteers
- 75 people
- Sponsor
- Sheba Medical Center
Advanced Non-small Cell Lung Cancer (NSCLC)
Impact of Liquid Biopsy on the Therapeutic Pathway for Lung Cancer: Advancing the Molecular Characterization of Patients With Advanced Lung Adenocarcinoma by Integrating Liquid Biopsy Into the Early Stages of the Diagnostic and Therapeutic Pathway
This multicenter pilot observational study aims to assess the feasibility of introducing liquid biopsy at an early stage of the diagnostic pathway for patients with suspected advanced non-small cell lung cancer (NSCLC).
- Trial name
- INNOVA-LUNG (NCT07649629)
- Testing
- Plasma-based liquid biopsy
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Regina Elena Cancer Institute
Peripheral Neuropathy, Multiple Myeloma, Neoplasms
Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)
This study aims at evaluating the possible beneficial role of Fenofibrate in attenuating the peripheral neuropathy associated with bortezomib (velcade), lenalidomide (revlimid), and dexamethasone (VRd) regimen in newly diagnosed…
- Trial name
- VRd MM Fibrate (NCT07025005)
- Testing
- Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg tablet, Bortezomib + Lenalidomide + Dexamethasone
- Where
- 2 sites in Egypt
- Volunteers
- 44 people
- Sponsor
- Tanta University
Multiple Myeloma in Relapse
Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.
Multiple myeloma is the second most common haematological cancer. Recent innovations have made it possible for relapsed/refractory patients to benefit from the innovative immunotherapy of bispecific antibodies.
- Trial name
- AmbuSpé (NCT06846905)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Toulouse
Amyloidosis, Primary, Cardiomyopathy
Molecular Imaging of Primary Amyloid Cardiomyopathy
Cardiac amyloidosis is a major cause of early treatment-related death and poor overall survival in individuals with systemic light chain amyloidosis.
- Trial name
- MICA (NCT02641145)
- Testing
- F-18 florbetapir/C-11 acetate PET, MRI, N-13 ammonia PET
- Where
- United States
- Volunteers
- 171 people
- Sponsor
- Brigham and Women's Hospital
Multiple Myeloma
A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)
The aim of this observational study is the creation of a national multiple myeloma registry to monitor the current routine clinical practice in Italy and describe the standard of care adopted for the diagnosis and treatment of…
- Trial name
- MY MYELOMA (NCT05001087)
- Testing
- Observation
- Where
- 27 sites in Italy
- Volunteers
- 1,900 people
- Sponsor
- Fondazione EMN Italy Onlus
Multiple Myeloma
Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
Primary Objective of the trial is to evaluate the efficacy and safety of Isa-VRd-based regimen in transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) patients receiving treatment in real-world clinical practice in…
- Trial name
- CHAMPION-01 (NCT07663253)
- Testing
- Isatuximab, Bortezomib, Lenalidomide
- Where
- 13 sites in China
- Volunteers
- 333 people
- Sponsor
- Shanghai Zhongshan Hospital
Multiple Myeloma (MM), Exercise
Effects of a Resistance Physical Exercise Program in Multiple Myeloma Patients
The goal of this clinical trial is to learn if physical exercise improves quality of life, frailty and mental health in patients with multiple myeloma. It will also learn about the safety and adherence of the program.
- Conditions
- Multiple Myeloma (MM), Exercise, Cancer
- Trial name
- NCT07253103
- Testing
- Supervised physical exercise, Home-based physical exercise program
- Volunteers
- 50 people
- Sponsor
- University of Salamanca
Plasma Cell Disorder
Disease Characteristics and Treatment Response in Plasma Cell Disorders Patients Based on Genetic Abnormalities From Fluorescence In Situ Hybridization and Next Generation Sequencing
The goal of this observational study is to study the genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand.
- Trial name
- genetics MM (NCT06330896)
- Volunteers
- 498 people
- Sponsor
- Siriraj Hospital
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Germ Cell Ovarian Cancer, Germ Cell Tumor
SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours
The goal of this observational case-control study is to learn about the circulating and tissue microRNA expression, imaging and radiomic profiles of malignant ovarian germ cell tumours (MOGCT) compared to patients with a benign…
- Conditions
- Germ Cell Ovarian Cancer, Germ Cell Tumor, Germ Cell Cancer, Germ Cell Neoplasia
- Trial name
- SUMMER (NCT06329323)
- Testing
- Blood test, Pathology specimen miRNA expression
- Volunteers
- 24 people
- Sponsor
- Imperial College London
Multiple Myeloma, Relapsed, Multiple Myeloma (MM)
Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
This is a non-interventional observational study aiming to evaluate the quality of life, efficacy, and safety of advanced immuno-oncology agents versus conventional immuno-oncology therapies in patients with relapsed or…
- Trial name
- NCT07051850
- Testing
- Bispecific antibody, Antibody-Drug Conjugate, Monoclonal antibody
- Where
- South Korea
- Volunteers
- 174 people
- Sponsor
- Sung-Soo Park
Multiple Myeloma (MM)
HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
This is a prospective, single-arm, exploratory Phase II clinical study evaluating the efficacy and safety of HP-001 capsules in combination with dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM) with…
- Trial name
- BEYOND-MM 001 (NCT07811986)
- Testing
- HP-001, Dexamethasone
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
CBC-Based Inflammatory Indices in Newly Diagnosed Multiple Myeloma
Multiple myeloma is a type of blood cancer characterized by the abnormal growth of plasma cells in the bone marrow. Increasing evidence indicates that interactions between myeloma cells and the host immune-inflammatory response…
- Trial name
- NCT07823959
- Volunteers
- 60 people
- Sponsor
- Assiut University